Biotechnology and Pharmaceuticals

March 10, 2017

Companies covered: ARCA biopharma, Inc. (NASDAQ:ABIO), Critical Outcome Technologies, Inc. (CVE:COT), NUVO PHARMACEUTICA COM NPV (OTCMKTS:NRIFF), Lipocine Inc. (NASDAQ:LPCN), Antibe Therapeutics Inc. (OTCMKTS:ATBPF), RepliCel Life Sciences Inc. (OTCMKTS:REPCF), La Jolla Pharmaceutical Company (NASDAQ:LJPC), Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP), Anavex Life Sciences Corp. (NASDAQ:AVXL), ESSA Pharma Inc. (NASDAQ:EPIX), OncoSec Medical Inc (NASDAQ:ONCS), BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), VBI Vaccines Inc. (NASDAQ:VBIV), Celyad SA (ADR) (NASDAQ:CYAD), MDXHealth SA (OTCMKTS:MXDHF), Biocartis Group NV (EBR:BCART), Galapagos NV (NASDAQ:GLPG), Thermo Fisher Scientific Inc (NYSE:TMO), Gilead Sciences, Inc. (NASDAQ:GILD), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), The Medicines Company (NASDAQ:MDCO), AveXis Inc (NASDAQ:AVXS), Amgen Inc. (NASDAQ:AMGN), Pfizer, Inc. (NYSE:PFE), Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Emergent Biosolutions, Inc. (NYSE:EBS), Spark Therapeutics, Inc. (NASDAQ:ONCE), Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH), Titan Pharmaceuticals, Inc. (NASDAQ:TTNP), Teva Pharmaceutical Industries Limited (NYSE:TEVA), Mylan Inc. (NASDAQ:MYL), Akorn, Inc. (NASDAQ:AKRX), Mallinckrodt plc (NYSE:MNK), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), Allergan, Inc. (NYSE:AGN), Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), Axovant Sciences Ltd (NYSE:AXON), Neurocrine Biosciences, Inc. (NASDAQ:NBIX), TherapeuticsMD, Inc. (AMEX:TXMD), ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), Prothena Corporation plc (NASDAQ:PRTA), Roche Holding Ltd. (ADR) (OTCMKTS:RHHBY), Biogen Inc. (NASDAQ:BIIB), Acorda Therapeutics, Inc. (NASDAQ:ACOR), Kite Pharma, Inc. (NASDAQ:KITE), FibroGen, Inc (NASDAQ:FGEN), Selecta Biosciences Inc (NASDAQ:SELB), vTv Therapeutics Inc (NASDAQ:VTVT), TRACON Pharmaceuticals, Inc. (NASDAQ:TCON), Clovis Oncology, Inc. (NASDAQ:CLVS), Puma Biotechnology Inc (NYSE:PBYI), Bioverativ Inc (NASDAQ:BIVV), Celgene Corporation (NASDAQ:CELG), Sanofi (NYSE:SNY), Novo Nordisk A/S (NYSE:NVO), GlaxoSmithKline PLC (NYSE:GSK), Novartis AG (NYSE:NVS)

Buy ($175)